Exelixis Acquires GamaMabs’ Oncology Antibody Program to Expand its Biotherapeutics Portfolio

 Exelixis Acquires GamaMabs’ Oncology Antibody Program to Expand its Biotherapeutics Portfolio

Shots:

  • Exelixis to acquire GamaMabs’ AMHR2 Ab technology for $5M and additionally payment upon achieving certain milestones. Following the closing of the transaction, Exelixis will control GamaMabs’ AMHR2 franchise technology including all assets related to murlentamab (GM-102)
  • The preclinical data support the potential of AMHR2 for novel oncology therapies and demonstrated the safety of an anti-AMHR2 mAbs in human clinical trials
  • Exelixis expands its biotherapeutics portfolio by integrating its ADC capabilities to GamaMabs’ Abs against AMHR2 and helps to provide rapid and effective development of cancer therapies

Click here to­ read full press release/ article | Ref: BUSINESS WIRE | Image: Exelixis

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post